Press Releases

Month Year

Month Year

Investor Alerts

Mar 15, 2022

Trevi Therapeutics Concludes Enrollment for Phase 2 CANAL Trial in IPF Chronic Cough
Mar 9, 2022

Trevi Therapeutics to Report Q4 and Year End 2021 Financial Results and Provide a Corporate Update on March 17, 2022

Conference Call and Webcast to be Held at 4:30 p.m. EDT
Feb 24, 2022

Trevi Therapeutics Reports Statistically Significant Result on Interim Analysis from the Ph2 CANAL Trial of Nalbuphine ER in the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis

Interim analysis showed primary efficacy endpoint of cough reduction was highly statistically significant (p<0.0001) for Haduvio (nalbuphine ER)
Feb 1, 2022

Trevi Therapeutics Completes Enrollment for Phase 2b/3 PRISM Study in Chronic Pruritus in PN

Top-Line Data Expected 2Q 2022
Jan 5, 2022

Trevi Therapeutics Announces Clinical Trial Updates for Lead Indications

Phase 2 CANAL (Chronic Cough in IPF) Planned Interim Statistical Update 1Q 2022, with Top-Line Data 1H 2022

Show per page

Media Contact

Katie McManus
(203) 903-9627
k.mcmanus@trevitherapeutics.com

Trevi Therapeutics
195 Church Street, 14th Floor
New Haven, CT 06510
map